Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03824730
Other study ID # CCSerbia Vasc
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2013
Est. completion date September 1, 2018

Study information

Verified date January 2019
Source Clinical Centre of Serbia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study compares early and long-term results of the endovascular treatment among patients with different types of aorto-iliac occlusions.


Description:

Endovascular treatment has been increasingly applied as a therapeutic option for aorto-iliac occlusive disease during the last decade, becoming the first-line treatment for many of the Trans-Atlantic Inter-Society Consensus document II (TASC II) categories. TASC II document in 2007 stated endovascular treatment as the method of choice up to type B occlusions and surgery for low-risk patients with type C and D occlusions, emphasizing that the patient's comorbidities as well as the operator's long-term success rates should be included in the decision-making process.

Revision of TASC II document in 2015 is suggesting that the preferred revascularization method should be based on each vascular center's competence and experience with the anatomic complexity, considering patient comorbidity and overall prognosis, supporting the endovascular-first approach in all 4 different kinds of lesions in highly experienced centers.

These changes over time are based on expert opinions derived from smaller studies from high volume centers, and that they reflect both the widespread gain of endovascular experience and technical developments over the last 2 decades, leading to a rising number of centers providing an endovascular-first approach even in complex TASC C and D occlusions.

Rationale for offering endovascular-first option to patient with complex lesion would be low risk of complication and long-term patency.

Our intention is to compare early and long-term results of the endovascular treatment among patients with different types of aorto-iliac occlusions in two Serbian vascular centres.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date September 1, 2018
Est. primary completion date November 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient has aorto-iliac occlusions type B, C & D according to TASC-II classification

- Patient suffers from severe claudication (Rutherford 3) or critical limb ischemia (Rutherford 4 and 5)

- Patients fulfilling criteria for endovascular treatment of aorto-iliac occlusion according to criteria of the participating centres.

Exclusion Criteria:

- Patients with associated abdominal or iliac aneurysm, restenotic lesions, acute thrombi or dissections,

- Patients who experienced an initial technical failure

Study Design


Intervention

Device:
Stenting of the Common and/or External Iliac Arteries
Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach. Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively. Predilatation of the occlusion before stent deployment was performed at the discretion of the operator. Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions. Both stents were used in long lesions involving heavily calcified common iliac arteries.

Locations

Country Name City State
Serbia Clinical Center of Serbia Belgrade
Serbia Institute for Cardiovascular Diseases Dedinje Belgrade

Sponsors (1)

Lead Sponsor Collaborator
Clinical Centre of Serbia

Country where clinical trial is conducted

Serbia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary artery/stent patency rate Patients were assumed primary patent if the target vessel had continuous flow without revascularization, bypass, or amputation. 60 Months
Secondary Primary assisted artery/stent patency rate Primary assisted patency is defined as continuous flow assisted with a revascularization when the target vessel has restenosed (>70%) at any time post-procedure. 60 months
Secondary Secondary patency artery/stent rate Secondary patency is defined as reestablishment of flow to distal arteries after 100% occlusion has occurred at the target vessel at any time post-procedure 60 months
Secondary Clinical success During the follow-up period, the improvement of Rutherford classification 1 grade or more than 1 grade. 60 months
Secondary Number of participants with periprocedural complications: hematoma, bleeding, pseudoaneurysm, renal failure, myocardial infarction, stroke, mortality, thrombosis of the treated segment Identification of serious adverse events requiring correction of therapy or surgery. Will be used physiological parameter and questionnaire. 1 month
See also
  Status Clinical Trial Phase
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Recruiting NCT05353309 - Iliac Angioplasties: Impact of the Fusion of Images on the Irradiation Rate N/A
Completed NCT03414515 - Endovascular Treatment of Peripheral Artery Disease (PAD)
Terminated NCT03346577 - Endovascular Treatment of Peripheral Artery Disease
Not yet recruiting NCT05229250 - NIRS and Exercise Intensity in Patients With FLIA
Withdrawn NCT04822727 - AndraTec PMCF Study : Investigating the AndraTec Guidewires,PTA Balloons and Stents in Iliac Disease.
Completed NCT03590769 - Arterial Imaging of Inflammation and Resolution After Endovascular Surgery Phase 1
Not yet recruiting NCT05192616 - Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease
Active, not recruiting NCT02698358 - Korean Multicenter Registry of EPIC Stent for Iliac Artery Disease: (K-EPIC Registry)